{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T01:06:09Z","timestamp":1752282369939,"version":"3.40.3"},"publisher-location":"Cham","reference-count":118,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783030550349"},{"type":"electronic","value":"9783030550356"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/978-3-030-55035-6_15","type":"book-chapter","created":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T16:07:20Z","timestamp":1615910840000},"page":"213-223","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeting Age-Related Neurodegenerative Diseases by\u00a0AAV-Mediated Gene Therapy"],"prefix":"10.1007","author":[{"given":"Umut","family":"Cagin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,17]]},"reference":[{"issue":"5","key":"15_CR1","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1007\/s12035-018-1334-z","volume":"56","author":"A Kurtishi","year":"2019","unstructured":"Kurtishi A, Rosen B, Patil KS, Alves GW, Moller SG (2019) Cellular proteostasis in neurodegeneration. Mol Neurobiol 56(5):3676\u20133689","journal-title":"Mol Neurobiol"},{"key":"15_CR2","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/978-3-319-53889-1_19","volume":"978","author":"MAS Pavlou","year":"2017","unstructured":"Pavlou MAS, Outeiro TF (2017) Epigenetics in Parkinson\u2019s disease. Adv Exp Med Biol 978:363\u2013390","journal-title":"Adv Exp Med Biol"},{"key":"15_CR3","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.biocel.2015.07.006","volume":"67","author":"JS Burchfield","year":"2015","unstructured":"Burchfield JS, Li Q, Wang HY, Wang RF (2015) JMJD3 as an epigenetic regulator in development and disease. Int J Biochem Cell Biol 67:148\u2013157","journal-title":"Int J Biochem Cell Biol"},{"issue":"1","key":"15_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10101-7","volume":"10","author":"P Li","year":"2019","unstructured":"Li P, Marshall L, Oh G, Jakubowski JL, Groot D, He Y et al (2019) Epigenetic dysregulation of enhancers in neurons is associated with Alzheimer's disease pathology and cognitive symptoms. Nat Commun 10(1):2246. https:\/\/doi.org\/10.1038\/s41467-019-10101-7","journal-title":"Nat Commun"},{"issue":"7113","key":"15_CR5","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nature05292","volume":"443","author":"MT Lin","year":"2006","unstructured":"Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443(7113):787\u2013795","journal-title":"Nature"},{"issue":"44","key":"15_CR6","doi-asserted-by":"publisher","first-page":"E6000","DOI":"10.1073\/pnas.1505036112","volume":"112","author":"U Cagin","year":"2015","unstructured":"Cagin U, Duncan OF, Gatt AP, Dionne MS, Sweeney ST, Bateman JM (2015) Mitochondrial retrograde signaling regulates neuronal function. Proc Natl Acad Sci U S A 112(44):E6000\u2013E6009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"15_CR7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/978-3-030-12668-1_5","volume":"1134","author":"E Casajus Pelegay","year":"2019","unstructured":"Casajus Pelegay E, Puzzo F, Yilmazer A, Cagin U (2019) Targeting mitochondrial defects to increase longevity in animal models of neurodegenerative diseases. Adv Exp Med Biol 1134:89\u2013110","journal-title":"Adv Exp Med Biol"},{"issue":"9","key":"15_CR8","doi-asserted-by":"publisher","first-page":"696","DOI":"10.2174\/1871527317666180816100203","volume":"17","author":"A Kumar","year":"2018","unstructured":"Kumar A, Dhawan A, Kadam A, Shinde A (2018) Autophagy and mitochondria: targets in neurodegenerative disorders. CNS Neurol Disord Drug Targets 17(9):696\u2013705","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"1","key":"15_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4103\/1673-5374.224362","volume":"13","author":"IG Onyango","year":"2018","unstructured":"Onyango IG (2018) Modulation of mitochondrial bioenergetics as a therapeutic strategy in Alzheimer's disease. Neural Regen Res 13(1):19\u201325","journal-title":"Neural Regen Res"},{"issue":"6","key":"15_CR10","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med 8(6):595\u2013608","journal-title":"EMBO Mol Med"},{"issue":"2","key":"15_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nm.4269","volume":"23","author":"YC Wong","year":"2017","unstructured":"Wong YC, Krainc D (2017) \u03b1-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nat Med 23(2):1\u201313","journal-title":"Nat Med"},{"key":"15_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-71779-1_1","volume":"1049","author":"R Ghosh","year":"2018","unstructured":"Ghosh R, Tabrizi SJ (2018) Clinical features of Huntington's disease. Adv Exp Med Biol 1049:1\u201328","journal-title":"Adv Exp Med Biol"},{"issue":"8","key":"15_CR13","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1080\/15548627.2017.1308985","volume":"13","author":"R Cristofani","year":"2017","unstructured":"Cristofani R, Crippa V, Rusmini P, Cicardi ME, Meroni M, Licata NV et al (2017) Inhibition of retrograde transport modulates misfolded protein accumulation and clearance in motoneuron diseases. Autophagy 13(8):1280\u20131303","journal-title":"Autophagy"},{"issue":"11","key":"15_CR14","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s00109-016-1461-9","volume":"94","author":"AR Ariosa","year":"2016","unstructured":"Ariosa AR, Klionsky DJ (2016) Autophagy core machinery: overcoming spatial barriers in neurons. J Mol Med (Berl) 94(11):1217\u20131227","journal-title":"J Mol Med (Berl)"},{"key":"15_CR15","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.trci.2019.05.008","volume":"5","author":"J Cummings","year":"2019","unstructured":"Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K (2019) Alzheimer's disease drug development pipeline: 2019. Alzheimers Dement (N Y) 5:272\u2013293","journal-title":"Alzheimers Dement (N Y)"},{"issue":"10110","key":"15_CR16","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1016\/S0140-6736(17)32399-1","volume":"390","author":"RM Anderson","year":"2017","unstructured":"Anderson RM, Hadjichrysanthou C, Evans S, Wong MM (2017) Why do so many clinical trials of therapies for Alzheimer\u2019s disease fail? Lancet 390(10110):2327\u20132329","journal-title":"Lancet"},{"issue":"5","key":"15_CR17","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.neuron.2019.02.017","volume":"101","author":"E Hudry","year":"2019","unstructured":"Hudry E, Vandenberghe LH (2019) Therapeutic AAV gene transfer to the nervous system: a clinical reality. Neuron 101(5):839\u2013862","journal-title":"Neuron"},{"issue":"9","key":"15_CR18","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/nrd.2018.110","volume":"17","author":"BE Deverman","year":"2018","unstructured":"Deverman BE, Ravina BM, Bankiewicz KS, Paul SM, Sah DWY (2018) Gene therapy for neurological disorders: progress and prospects. Nat Rev Drug Discov 17(9):641\u2013659","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"15_CR19","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.ymthe.2019.11.012","volume":"28","author":"T Taghian","year":"2020","unstructured":"Taghian T, Marosfoi MG, Puri AS, Cataltepe OI, King RM, Diffie EB et al (2020) A safe and reliable technique for CNS delivery of AAV vectors in the Cisterna Magna. Mol Ther 28(2):411\u2013421","journal-title":"Mol Ther"},{"issue":"98","key":"15_CR20","first-page":"151","volume":"18","author":"D Wang","year":"2014","unstructured":"Wang D, Gao G (2014) State-of-the-art human gene therapy: Part II. Gene therapy strategies and clinical applications. Discov Med 18(98):151\u2013161","journal-title":"Discov Med"},{"key":"15_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1146\/annurev-bioeng-071813-104938","volume":"17","author":"MA Kotterman","year":"2015","unstructured":"Kotterman MA, Chalberg TW, Schaffer DV (2015) Viral vectors for gene therapy: translational and clinical outlook. Annu Rev Biomed Eng 17:63\u201389","journal-title":"Annu Rev Biomed Eng"},{"issue":"5","key":"15_CR22","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nrg2988","volume":"12","author":"F Mingozzi","year":"2011","unstructured":"Mingozzi F, High KA (2011) Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 12(5):341\u2013355","journal-title":"Nat Rev Genet"},{"issue":"26","key":"15_CR23","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","volume":"377","author":"S Rangarajan","year":"2017","unstructured":"Rangarajan S, Walsh L, Lester W, Perry D, Madan B, Laffan M et al (2017) AAV5-Factor VIII gene transfer in severe Hemophilia A. N Engl J Med 377(26):2519\u20132530","journal-title":"N Engl J Med"},{"issue":"25","key":"15_CR24","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","volume":"365","author":"AC Nathwani","year":"2011","unstructured":"Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC et al (2011) Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365(25):2357\u20132365","journal-title":"N Engl J Med"},{"issue":"21","key":"15_CR25","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","volume":"371","author":"AC Nathwani","year":"2014","unstructured":"Nathwani AC, Reiss UM, Tuddenham EG, Rosales C, Chowdary P, McIntosh J et al (2014) Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 371(21):1994\u20132004","journal-title":"N Engl J Med"},{"issue":"23","key":"15_CR26","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","volume":"377","author":"LA George","year":"2017","unstructured":"George LA, Sullivan SK, Giermasz A, Rasko JEJ, Samelson-Jones BJ, Ducore J et al (2017) Hemophilia B gene therapy with a high-specific-activity Factor IX variant. N Engl J Med 377(23):2215\u20132227","journal-title":"N Engl J Med"},{"issue":"21","key":"15_CR27","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1056\/NEJMoa0802315","volume":"358","author":"AM Maguire","year":"2008","unstructured":"Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F, Bennicelli J, Banfi S, Marshall KA, Testa F, Surace EM et al (2008) Safety and efficacy of gene transfer for Leber\u2019s congenital amaurosis. N Engl J Med 358(21):2240\u20132248","journal-title":"N Engl J Med"},{"issue":"21","key":"15_CR28","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1056\/NEJMoa0802268","volume":"358","author":"JW Bainbridge","year":"2008","unstructured":"Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K et al (2008) Effect of gene therapy on visual function in Leber\u2019s congenital amaurosis. N Engl J Med 358(21):2231\u20132239","journal-title":"N Engl J Med"},{"issue":"20","key":"15_CR29","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1056\/NEJMoa1414221","volume":"372","author":"JW Bainbridge","year":"2015","unstructured":"Bainbridge JW, Mehat MS, Sundaram V, Robbie SJ, Barker SE, Ripamonti C et al (2015) Long-term effect of gene therapy on Leber\u2019s congenital amaurosis. N Engl J Med 372(20):1887\u20131897","journal-title":"N Engl J Med"},{"issue":"18","key":"15_CR30","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW et al (2017) Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 377(18):1713\u20131722","journal-title":"N Engl J Med"},{"issue":"2","key":"15_CR31","doi-asserted-by":"publisher","first-page":"86","DOI":"10.2174\/1566523214666140302193709","volume":"14","author":"B Balakrishnan","year":"2014","unstructured":"Balakrishnan B, Jayandharan GR (2014) Basic biology of adeno-associated virus (AAV) vectors used in gene therapy. Curr Gene Ther 14(2):86\u2013100","journal-title":"Curr Gene Ther"},{"issue":"22","key":"15_CR32","doi-asserted-by":"publisher","first-page":"10220","DOI":"10.1073\/pnas.1001673107","volume":"107","author":"F Sonntag","year":"2010","unstructured":"Sonntag F, Schmidt K, Kleinschmidt JA (2010) A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl Acad Sci U S A 107(22):10220\u201310225","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"15_CR33","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/gt.2009.157","volume":"17","author":"E Ayuso","year":"2010","unstructured":"Ayuso E, Mingozzi F, Montane J, Leon X, Anguela XM, Haurigot V et al (2010) High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency. Gene Ther 17(4):503\u2013510","journal-title":"Gene Ther"},{"issue":"11","key":"15_CR34","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/gt.2008.65","volume":"15","author":"JF Wright","year":"2008","unstructured":"Wright JF (2008) Manufacturing and characterizing AAV-based vectors for use in clinical studies. Gene Ther 15(11):840\u2013848","journal-title":"Gene Ther"},{"issue":"6","key":"15_CR35","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2174\/156652310793797685","volume":"10","author":"E Ayuso","year":"2010","unstructured":"Ayuso E, Mingozzi F, Bosch F (2010) Production, purification and characterization of adeno-associated vectors. Curr Gene Ther 10(6):423\u2013436","journal-title":"Curr Gene Ther"},{"issue":"1","key":"15_CR36","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/mt.2009.258","volume":"18","author":"B Dong","year":"2010","unstructured":"Dong B, Nakai H, Xiao W (2010) Characterization of genome integrity for oversized recombinant AAV vector. Mol Ther 18(1):87\u201392","journal-title":"Mol Ther"},{"issue":"1","key":"15_CR37","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/mt.2009.255","volume":"18","author":"Z Wu","year":"2010","unstructured":"Wu Z, Yang H, Colosi P (2010) Effect of genome size on AAV vector packaging. Mol Ther 18(1):80\u201386","journal-title":"Mol Ther"},{"key":"15_CR38","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/02648725.2007.10648098","volume":"24","author":"A Ghosh","year":"2007","unstructured":"Ghosh A, Duan D (2007) Expanding adeno-associated viral vector capacity: a tale of two vectors. Biotechnol Genet Eng Rev 24:165\u2013177","journal-title":"Biotechnol Genet Eng Rev"},{"issue":"2","key":"15_CR39","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/emmm.201302948","volume":"6","author":"I Trapani","year":"2014","unstructured":"Trapani I, Colella P, Sommella A, Iodice C, Cesi G, de Simone S et al (2014) Effective delivery of large genes to the retina by dual AAV vectors. EMBO Mol Med 6(2):194\u2013211","journal-title":"EMBO Mol Med"},{"issue":"4","key":"15_CR40","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/gt.2014.8","volume":"21","author":"P Colella","year":"2014","unstructured":"Colella P, Trapani I, Cesi G, Sommella A, Manfredi A, Puppo A et al (2014) Efficient gene delivery to the cone-enriched pig retina by dual AAV vectors. Gene Ther 21(4):450\u2013456","journal-title":"Gene Ther"},{"issue":"23","key":"15_CR41","doi-asserted-by":"publisher","first-page":"6811","DOI":"10.1093\/hmg\/ddv386","volume":"24","author":"I Trapani","year":"2015","unstructured":"Trapani I, Toriello E, de Simone S, Colella P, Iodice C, Polishchuk EV et al (2015) Improved dual AAV vectors with reduced expression of truncated proteins are safe and effective in the retina of a mouse model of Stargardt disease. Hum Mol Genet 24(23):6811\u20136825","journal-title":"Hum Mol Genet"},{"issue":"10","key":"15_CR42","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1093\/hmg\/ddq065","volume":"19","author":"W Lostal","year":"2010","unstructured":"Lostal W, Bartoli M, Bourg N, Roudaut C, Bentaib A, Miyake K et al (2010) Efficient recovery of dysferlin deficiency by dual adeno-associated vector-mediated gene transfer. Hum Mol Genet 19(10):1897\u20131907","journal-title":"Hum Mol Genet"},{"issue":"3","key":"15_CR43","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/acn3.172","volume":"2","author":"PC Sondergaard","year":"2015","unstructured":"Sondergaard PC, Griffin DA, Pozsgai ER, Johnson RW, Grose WE, Heller KN et al (2015) AAV. Dysferlin overlap vectors restore function in dysferlinopathy animal models. Ann Clin Transl Neurol 2(3):256\u2013270","journal-title":"Ann Clin Transl Neurol"},{"issue":"7","key":"15_CR44","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1089\/hum.2017.062","volume":"29","author":"RA Potter","year":"2018","unstructured":"Potter RA, Griffin DA, Sondergaard PC, Johnson RW, Pozsgai ER, Heller KN et al (2018) Systemic delivery of dysferlin overlap vectors provides long-term gene expression and functional improvement for dysferlinopathy. Hum Gene Ther 29(7):749\u2013762","journal-title":"Hum Gene Ther"},{"issue":"3","key":"15_CR45","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1089\/hum.2017.095","volume":"29","author":"K Kodippili","year":"2018","unstructured":"Kodippili K, Hakim CH, Pan X, Yang HT, Yue Y, Zhang Y et al (2018) Dual AAV gene therapy for duchenne muscular dystrophy with a 7-kb mini-dystrophin gene in the canine model. Hum Gene Ther 29(3):299\u2013311","journal-title":"Hum Gene Ther"},{"issue":"3","key":"15_CR46","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2174\/1566523054065057","volume":"5","author":"G Gao","year":"2005","unstructured":"Gao G, Vandenberghe LH, Wilson JM (2005) New recombinant serotypes of AAV vectors. Curr Gene Ther 5(3):285\u2013297","journal-title":"Curr Gene Ther"},{"issue":"4","key":"15_CR47","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/mt.2011.287","volume":"20","author":"A Asokan","year":"2012","unstructured":"Asokan A, Schaffer DV, Samulski RJ (2012) The AAV vector toolkit: poised at the clinical crossroads. Mol Ther 20(4):699\u2013708","journal-title":"Mol Ther"},{"issue":"7588","key":"15_CR48","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature16465","volume":"530","author":"S Pillay","year":"2016","unstructured":"Pillay S, Meyer NL, Puschnik AS, Davulcu O, Diep J, Ishikawa Y et al (2016) An essential receptor for adeno-associated virus infection. Nature 530(7588):108\u2013112","journal-title":"Nature"},{"issue":"2","key":"15_CR49","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ymthe.2019.11.005","volume":"28","author":"AM Dudek","year":"2020","unstructured":"Dudek AM, Zabaleta N, Zinn E, Pillay S, Zengel J, Porter C et al (2020) GPR108 is a highly conserved AAV entry factor. Mol Ther 28(2):367\u2013381","journal-title":"Mol Ther"},{"key":"15_CR50","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","volume":"8","author":"P Colella","year":"2018","unstructured":"Colella P, Ronzitti G, Mingozzi F (2018) Emerging issues in AAV-mediated in vivo gene therapy. Mol Ther Methods Clin Dev 8:87\u2013104","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"4","key":"15_CR51","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/nm1549","volume":"13","author":"F Mingozzi","year":"2007","unstructured":"Mingozzi F, Maus MV, Hui DJ, Sabatino DE, Murphy SL, Rasko JE et al (2007) CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med 13(4):419\u2013422","journal-title":"Nat Med"},{"issue":"1","key":"15_CR52","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1038\/s41467-018-06621-3","volume":"9","author":"A Meliani","year":"2018","unstructured":"Meliani A, Boisgerault F, Hardet R, Marmier S, Collaud F, Ronzitti G et al (2018) Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration. Nat Commun 9(1):4098. https:\/\/doi.org\/10.1038\/s41467-018-06621-3","journal-title":"Nat Commun"},{"issue":"17","key":"15_CR53","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1182\/bloodadvances.2019000380","volume":"3","author":"D Salas","year":"2019","unstructured":"Salas D, Kwikkers KL, Zabaleta N, Bazo A, Petry H, van Deventer SJ et al (2019) Immunoadsorption enables successful rAAV5-mediated repeated hepatic gene delivery in nonhuman primates. Blood Adv 3(17):2632\u20132641","journal-title":"Blood Adv"},{"issue":"1","key":"15_CR54","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/s41598-020-57893-z","volume":"10","author":"B Bertin","year":"2020","unstructured":"Bertin B, Veron P, Leborgne C, Deschamps JY, Moullec S, Fromes Y et al (2020) Capsid-specific removal of circulating antibodies to adeno-associated virus vectors. Sci Rep 10(1):864. https:\/\/doi.org\/10.1038\/s41598-020-57893-z","journal-title":"Sci Rep"},{"issue":"3","key":"15_CR55","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","volume":"28","author":"HC Verdera","year":"2020","unstructured":"Verdera HC, Kuranda K, Mingozzi F (2020) AAV Vector immunogenicity in humans: a long journey to successful gene transfer. Mol Ther 28(3):723\u2013746","journal-title":"Mol Ther"},{"issue":"26","key":"15_CR56","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1093\/hmg\/10.26.3075","volume":"10","author":"A Auricchio","year":"2001","unstructured":"Auricchio A, Kobinger G, Anand V, Hildinger M, O'Connor E, Maguire AM et al (2001) Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. Hum Mol Genet 10(26):3075\u20133081","journal-title":"Hum Mol Genet"},{"issue":"11","key":"15_CR57","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1089\/hum.2017.172","volume":"28","author":"D Grimm","year":"2017","unstructured":"Grimm D, Buning H (2017) Small but increasingly mighty: latest advances in AAV vector research, design, and evolution. Hum Gene Ther 28(11):1075\u20131086","journal-title":"Hum Gene Ther"},{"issue":"3","key":"15_CR58","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/nm1358","volume":"12","author":"CS Manno","year":"2006","unstructured":"Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ et al (2006) Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12(3):342\u2013347","journal-title":"Nat Med"},{"issue":"10","key":"15_CR59","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1182\/blood-2008-07-167510","volume":"114","author":"F Mingozzi","year":"2009","unstructured":"Mingozzi F, Meulenberg JJ, Hui DJ, Basner-Tschakarjan E, Hasbrouck NC, Edmonson SA et al (2009) AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood 114(10):2077\u20132086","journal-title":"Blood"},{"issue":"10","key":"15_CR60","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/nm.2025","volume":"15","author":"YH Chen","year":"2009","unstructured":"Chen YH, Chang M, Davidson BL (2009) Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy. Nat Med 15(10):1215\u20131218","journal-title":"Nat Med"},{"issue":"2","key":"15_CR61","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ymthe.2004.05.024","volume":"10","author":"C Burger","year":"2004","unstructured":"Burger C, Gorbatyuk OS, Velardo MJ, Peden CS, Williams P, Zolotukhin S et al (2004) Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 10(2):302\u2013317","journal-title":"Mol Ther"},{"issue":"3","key":"15_CR62","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1089\/hum.2006.178","volume":"18","author":"JM Taymans","year":"2007","unstructured":"Taymans JM, Vandenberghe LH, Haute CV, Thiry I, Deroose CM, Mortelmans L et al (2007) Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. Hum Gene Ther 18(3):195\u2013206","journal-title":"Hum Gene Ther"},{"issue":"9","key":"15_CR63","doi-asserted-by":"publisher","first-page":"e76310","DOI":"10.1371\/journal.pone.0076310","volume":"8","author":"DF Aschauer","year":"2013","unstructured":"Aschauer DF, Kreuz S, Rumpel S (2013) Analysis of transduction efficiency, tropism and axonal transport of AAV serotypes 1, 2, 5, 6, 8 and 9 in the mouse brain. PLoS One 8(9):e76310. https:\/\/doi.org\/10.1371\/journal.pone.0076310","journal-title":"PLoS One"},{"issue":"22","key":"15_CR64","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/sj.gt.3302087","volume":"10","author":"CH Vite","year":"2003","unstructured":"Vite CH, Passini MA, Haskins ME, Wolfe JH (2003) Adeno-associated virus vector-mediated transduction in the cat brain. Gene Ther 10(22):1874\u20131881","journal-title":"Gene Ther"},{"issue":"1","key":"15_CR65","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/gt.2013.54","volume":"21","author":"GP Swain","year":"2014","unstructured":"Swain GP, Prociuk M, Bagel JH, O'Donnell P, Berger K, Drobatz K et al (2014) Adeno-associated virus serotypes 9 and rh10 mediate strong neuronal transduction of the dog brain. Gene Ther 21(1):28\u201336","journal-title":"Gene Ther"},{"key":"15_CR66","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.neures.2014.09.002","volume":"93","author":"A Watakabe","year":"2015","unstructured":"Watakabe A, Ohtsuka M, Kinoshita M, Takaji M, Isa K, Mizukami H et al (2015) Comparative analyses of adeno-associated viral vector serotypes 1, 2, 5, 8 and 9 in marmoset, mouse and macaque cerebral cortex. Neurosci Res 93:144\u2013157","journal-title":"Neurosci Res"},{"issue":"1","key":"15_CR67","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nbt.1515","volume":"27","author":"KD Foust","year":"2009","unstructured":"Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK (2009) Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 27(1):59\u201365","journal-title":"Nat Biotechnol"},{"key":"15_CR68","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.neulet.2014.05.044","volume":"576","author":"JR McLean","year":"2014","unstructured":"McLean JR, Smith GA, Rocha EM, Hayes MA, Beagan JA, Hallett PJ et al (2014) Widespread neuron-specific transgene expression in brain and spinal cord following synapsin promoter-driven AAV9 neonatal intracerebroventricular injection. Neurosci Lett 576:73\u201378","journal-title":"Neurosci Lett"},{"issue":"6","key":"15_CR69","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/mt.2011.72","volume":"19","author":"SJ Gray","year":"2011","unstructured":"Gray SJ, Matagne V, Bachaboina L, Yadav S, Ojeda SR, Samulski RJ (2011) Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther 19(6):1058\u20131069","journal-title":"Mol Ther"},{"issue":"6","key":"15_CR70","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1089\/hum.2009.182","volume":"21","author":"S Boutin","year":"2010","unstructured":"Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus MF et al (2010) Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther 21(6):704\u2013712","journal-title":"Hum Gene Ther"},{"issue":"10","key":"15_CR71","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1016\/j.ymthe.2018.07.008","volume":"26","author":"J Naidoo","year":"2018","unstructured":"Naidoo J, Stanek LM, Ohno K, Trewman S, Samaranch L, Hadaczek P et al (2018) extensive transduction and enhanced spread of a modified AAV2 Capsid in the non-human primate CNS. Mol Ther 26(10):2418\u20132430","journal-title":"Mol Ther"},{"issue":"4","key":"15_CR72","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/mt.2015.231","volume":"24","author":"SR Choudhury","year":"2016","unstructured":"Choudhury SR, Harris AF, Cabral DJ, Keeler AM, Sapp E, Ferreira JS et al (2016) Widespread central nervous system gene transfer and silencing after systemic delivery of novel AAV-AS vector. Mol Ther 24(4):726\u2013735","journal-title":"Mol Ther"},{"issue":"7","key":"15_CR73","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1038\/mt.2016.84","volume":"24","author":"SR Choudhury","year":"2016","unstructured":"Choudhury SR, Fitzpatrick Z, Harris AF, Maitland SA, Ferreira JS, Zhang Y et al (2016) In vivo selection yields AAV-B1 Capsid for central nervous system and muscle gene therapy. Mol Ther 24(7):1247\u20131257","journal-title":"Mol Ther"},{"key":"15_CR74","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.omtm.2019.10.007","volume":"15","author":"KS Hanlon","year":"2019","unstructured":"Hanlon KS, Meltzer JC, Buzhdygan T, Cheng MJ, Sena-Esteves M, Bennett RE et al (2019) Selection of an efficient AAV vector for robust CNS transgene expression. Mol Ther Methods Clin Dev 15:320\u2013332","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"2","key":"15_CR75","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nbt.3440","volume":"34","author":"BE Deverman","year":"2016","unstructured":"Deverman BE, Pravdo PL, Simpson BP, Kumar SR, Chan KY, Banerjee A et al (2016) Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol 34(2):204\u2013209","journal-title":"Nat Biotechnol"},{"key":"15_CR76","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.neulet.2017.11.049","volume":"665","author":"Y Matsuzaki","year":"2018","unstructured":"Matsuzaki Y, Konno A, Mochizuki R, Shinohara Y, Nitta K, Okada Y et al (2018) Intravenous administration of the adeno-associated virus-PHP.B capsid fails to upregulate transduction efficiency in the marmoset brain. Neurosci Lett 665:182\u2013188","journal-title":"Neurosci Lett"},{"issue":"3","key":"15_CR77","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.ymthe.2018.01.018","volume":"26","author":"J Hordeaux","year":"2018","unstructured":"Hordeaux J, Wang Q, Katz N, Buza EL, Bell P, Wilson JM (2018) The neurotropic properties of AAV-PHP.B are limited to C57BL\/6J Mice. Mol Ther 26(3):664\u2013668","journal-title":"Mol Ther"},{"issue":"11","key":"15_CR78","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/j.ymthe.2019.07.017","volume":"27","author":"WA Liguore","year":"2019","unstructured":"Liguore WA, Domire JS, Button D, Wang Y, Dufour BD, Srinivasan S et al (2019) AAV-PHP.B Administration results in a differential pattern of CNS biodistribution in non-human primates compared with mice. Mol Ther 27(11):2018\u20132037","journal-title":"Mol Ther"},{"issue":"12","key":"15_CR79","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1016\/j.ymthe.2017.08.004","volume":"25","author":"G Morabito","year":"2017","unstructured":"Morabito G, Giannelli SG, Ordazzo G, Bido S, Castoldi V, Indrigo M et al (2017) AAV-PHP.B-Mediated global-scale expression in the mouse nervous system enables GBA1 gene therapy for wide protection from synucleinopathy. Mol Ther 25(12):2727\u20132742","journal-title":"Mol Ther"},{"issue":"9770","key":"15_CR80","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/S0140-6736(10)61349-9","volume":"377","author":"C Ballard","year":"2011","unstructured":"Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E (2011) Alzheimer\u2019s disease. Lancet 377(9770):1019\u20131031","journal-title":"Lancet"},{"issue":"6","key":"15_CR81","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nrn3880","volume":"16","author":"FL Heppner","year":"2015","unstructured":"Heppner FL, Ransohoff RM, Becher B (2015) Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci 16(6):358\u2013372","journal-title":"Nat Rev Neurosci"},{"issue":"3","key":"15_CR82","first-page":"826","volume":"140","author":"S Alves","year":"2017","unstructured":"Alves S, Churlaud G, Audrain M, Michaelsen-Preusse K, Fol R, Souchet B et al (2017) Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer\u2019s disease mice. Brain 140(3):826\u2013842","journal-title":"Brain"},{"issue":"11","key":"15_CR83","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1038\/mt.2015.142","volume":"23","author":"T Kiyota","year":"2015","unstructured":"Kiyota T, Zhang G, Morrison CM, Bosch ME, Weir RA, Lu Y et al (2015) AAV2\/1 CD74 Gene transfer reduces beta-amyloidosis and improves learning and memory in a mouse model of Alzheime\u2019s disease. Mol Ther 23(11):1712\u20131721","journal-title":"Mol Ther"},{"issue":"7","key":"15_CR84","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaneurol.2018.0233","volume":"75","author":"MS Rafii","year":"2018","unstructured":"Rafii MS, Tuszynski MH, Thomas RG, Barba D, Brewer JB, Team ANS et al (2018) Adeno-associated viral vector (serotype 2)-nerve growth factor for patients with Alzheimer disease: a randomized clinical trial. JAMA Neurol 75(7):834\u2013841","journal-title":"JAMA Neurol"},{"issue":"7\u20138","key":"15_CR85","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1089\/hum.2019.367","volume":"31","author":"MJ Castle","year":"2020","unstructured":"Castle MJ, Baltanas FC, Kovacs I, Nagahara AH, Barba D, Tuszynski MH (2020) Postmortem analysis in a clinical trial of AAV2-NGF gene therapy for Alzheimer\u2019s disease identifies a need for improved vector delivery. Hum Gene Ther 31(7\u20138):415\u2013422","journal-title":"Hum Gene Ther"},{"key":"15_CR86","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.neurobiolaging.2016.04.020","volume":"44","author":"L Zhao","year":"2016","unstructured":"Zhao L, Gottesdiener AJ, Parmar M, Li M, Kaminsky SM, Chiuchiolo MJ et al (2016) Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer\u2019s disease mouse models. Neurobiol Aging 44:159\u2013117","journal-title":"Neurobiol Aging"},{"issue":"1","key":"15_CR87","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1089\/humc.2017.231","volume":"29","author":"JB Rosenberg","year":"2018","unstructured":"Rosenberg JB, Kaplitt MG, De BP, Chen A, Flagiello T, Salami C et al (2018) AAVrh.10-Mediated APOE2 central nervous system gene therapy for APOE4-associated Alzheimer\u2019s disease. Hum Gene Ther Clin Dev 29(1):24\u201347","journal-title":"Hum Gene Ther Clin Dev"},{"issue":"8","key":"15_CR88","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s40263-018-0548-y","volume":"32","author":"D Athauda","year":"2018","unstructured":"Athauda D, Foltynie T (2018) Drug repurposing in Parkinson\u2019s disease. CNS Drugs 32(8):747\u2013761","journal-title":"CNS Drugs"},{"issue":"3","key":"15_CR89","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00702-017-1681-3","volume":"125","author":"D Pignataro","year":"2018","unstructured":"Pignataro D, Sucunza D, Rico AJ, Dopeso-Reyes IG, Roda E, Rodriguez-Perez AI et al (2018) Gene therapy approaches in the non-human primate model of Parkinson\u2019s disease. J Neural Transm (Vienna) 125(3):575\u2013589","journal-title":"J Neural Transm (Vienna)"},{"key":"15_CR90","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.parkreldis.2019.07.018","volume":"66","author":"FL Hitti","year":"2019","unstructured":"Hitti FL, Yang AI, Gonzalez-Alegre P, Baltuch GH (2019) Human gene therapy approaches for the treatment of Parkinson\u2019s disease: an overview of current and completed clinical trials. Parkinsonism Relat Disord 66:16\u201324","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"15_CR91","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1089\/hum.2011.220","volume":"23","author":"G Mittermeyer","year":"2012","unstructured":"Mittermeyer G, Christine CW, Rosenbluth KH, Baker SL, Starr P, Larson P et al (2012) Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson\u2019s disease. Hum Gene Ther 23(4):377\u2013381","journal-title":"Hum Gene Ther"},{"issue":"21","key":"15_CR92","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1212\/01.wnl.0000312381.29287.ff","volume":"70","author":"JL Eberling","year":"2008","unstructured":"Eberling JL, Jagust WJ, Christine CW, Starr P, Larson P, Bankiewicz KS et al (2008) Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 70(21):1980\u20131983","journal-title":"Neurology"},{"issue":"5","key":"15_CR93","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ana.25450","volume":"85","author":"CW Christine","year":"2019","unstructured":"Christine CW, Bankiewicz KS, Van Laar AD, Richardson RM, Ravina B, Kells AP et al (2019) Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson\u2019s disease. Ann Neurol 85(5):704\u2013714","journal-title":"Ann Neurol"},{"issue":"9923","key":"15_CR94","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/S0140-6736(13)61939-X","volume":"383","author":"S Palfi","year":"2014","unstructured":"Palfi S, Gurruchaga JM, Ralph GS, Lepetit H, Lavisse S, Buttery PC et al (2014) Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1\/2 trial. Lancet 383(9923):1138\u20131146","journal-title":"Lancet"},{"issue":"3","key":"15_CR95","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1089\/humc.2016.056","volume":"27","author":"HJ Stewart","year":"2016","unstructured":"Stewart HJ, Ralph GS, Fong-Wong L, Strickland I, McCloskey L, Barnes L et al (2016) Optimizing transgene configuration and protein fusions to maximize dopamine production for the gene therapy of Parkinson\u2019s disease. Hum Gene Ther Clin Dev 27(3):100\u2013110","journal-title":"Hum Gene Ther Clin Dev"},{"key":"15_CR96","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.omtm.2019.07.002","volume":"14","author":"RA Badin","year":"2019","unstructured":"Badin RA, Binley K, Van Camp N, Jan C, Gourlay J, Robert C et al (2019) Gene therapy for Parkinson\u2019s disease: preclinical evaluation of optimally configured TH:CH1 fusion for maximal dopamine synthesis. Mol Ther Methods Clin Dev 14:206\u2013216","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"3","key":"15_CR97","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/ana.20737","volume":"59","author":"AE Lang","year":"2006","unstructured":"Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R et al (2006) Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 59(3):459\u2013466","journal-title":"Ann Neurol"},{"issue":"1","key":"15_CR98","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1212\/WNL.60.1.69","volume":"60","author":"JG Nutt","year":"2003","unstructured":"Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER Jr et al (2003) Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60(1):69\u201373","journal-title":"Neurology"},{"issue":"5","key":"15_CR99","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S1474-4422(08)70065-6","volume":"7","author":"WJ Marks Jr","year":"2008","unstructured":"Marks WJ Jr, Ostrem JL, Verhagen L, Starr PA, Larson PS, Bakay RA et al (2008) Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson\u2019s disease: an open-label, phase I trial. Lancet Neurol 7(5):400\u2013408","journal-title":"Lancet Neurol"},{"issue":"12","key":"15_CR100","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","volume":"9","author":"WJ Marks Jr","year":"2010","unstructured":"Marks WJ Jr, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N et al (2010) Gene delivery of AAV2-neurturin for Parkinson\u2019s disease: a double-blind, randomised, controlled trial. Lancet Neurol 9(12):1164\u20131172","journal-title":"Lancet Neurol"},{"issue":"2","key":"15_CR101","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/ana.24436","volume":"78","author":"C Warren Olanow","year":"2015","unstructured":"Warren Olanow C, Bartus RT, Baumann TL, Factor S, Boulis N, Stacy M et al (2015) Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: a double-blind, randomized, controlled trial. Ann Neurol 78(2):248\u2013257","journal-title":"Ann Neurol"},{"issue":"4","key":"15_CR102","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1474-4422(11)70039-4","volume":"10","author":"PA LeWitt","year":"2011","unstructured":"LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN et al (2011) AAV2-GAD gene therapy for advanced Parkinson\u2019s disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 10(4):309\u2013319","journal-title":"Lancet Neurol"},{"issue":"7","key":"15_CR103","doi-asserted-by":"publisher","first-page":"e90133","DOI":"10.1172\/jci.insight.90133","volume":"2","author":"M Niethammer","year":"2017","unstructured":"Niethammer M, Tang CC, LeWitt PA, Rezai AR, Leehey MA, Ojemann SG et al (2017) Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson\u2019s disease. JCI Insight 2(7):e90133. https:\/\/doi.org\/10.1172\/jci.insight.90133","journal-title":"JCI Insight"},{"issue":"2","key":"15_CR104","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3233\/JPD-181331","volume":"8","author":"TM Axelsen","year":"2018","unstructured":"Axelsen TM, Woldbye DPD (2018) Gene therapy for Parkinson\u2019s disease, an update. J Parkinsons Dis 8(2):195\u2013215","journal-title":"J Parkinsons Dis"},{"issue":"9769","key":"15_CR105","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/S0140-6736(10)61156-7","volume":"377","author":"MC Kiernan","year":"2011","unstructured":"Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O et al (2011) Amyotrophic lateral sclerosis. Lancet 377(9769):942\u2013955","journal-title":"Lancet"},{"issue":"4","key":"15_CR106","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ncl.2015.07.006","volume":"33","author":"JM Statland","year":"2015","unstructured":"Statland JM, Barohn RJ, McVey AL, Katz JS, Dimachkie MM (2015) Patterns of weakness, classification of motor neuron disease, and clinical diagnosis of sporadic amyotrophic lateral sclerosis. Neurol Clin 33(4):735\u2013748","journal-title":"Neurol Clin"},{"issue":"12","key":"15_CR107","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1038\/mt.2013.211","volume":"21","author":"KD Foust","year":"2013","unstructured":"Foust KD, Salazar DL, Likhite S, Ferraiuolo L, Ditsworth D, Ilieva H et al (2013) Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS. Mol Ther 21(12):2148\u20132159","journal-title":"Mol Ther"},{"key":"15_CR108","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.omtn.2018.04.015","volume":"12","author":"T Iannitti","year":"2018","unstructured":"Iannitti T, Scarrott JM, Likhite S, Coldicott IRP, Lewis KE, Heath PR et al (2018) Translating SOD1 gene silencing toward the clinic: a highly efficacious, off-target-free, and biomarker-supported strategy for fALS. Mol Ther Nucleic Acids 12:75\u201388","journal-title":"Mol Ther Nucleic Acids"},{"issue":"3","key":"15_CR109","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1093\/hmg\/ddt454","volume":"23","author":"H Wang","year":"2014","unstructured":"Wang H, Yang B, Qiu L, Yang C, Kramer J, Su Q et al (2014) Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis. Hum Mol Genet 23(3):668\u2013681","journal-title":"Hum Mol Genet"},{"issue":"1","key":"15_CR110","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1089\/hum.2015.122","volume":"27","author":"F Borel","year":"2016","unstructured":"Borel F, Gernoux G, Cardozo B, Metterville JP, Toro Cabrera GC, Song L et al (2016) Therapeutic rAAVrh10 mediated SOD1 silencing in adult SOD1(G93A) mice and nonhuman primates. Hum Gene Ther 27(1):19\u201331","journal-title":"Hum Gene Ther"},{"issue":"4","key":"15_CR111","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/ana.24618","volume":"79","author":"L Stoica","year":"2016","unstructured":"Stoica L, Todeasa SH, Cabrera GT, Salameh JS, ElMallah MK, Mueller C et al (2016) Adeno-associated virus-delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model. Ann Neurol 79(4):687\u2013700","journal-title":"Ann Neurol"},{"issue":"465","key":"15_CR112","doi-asserted-by":"publisher","first-page":"eaau6414","DOI":"10.1126\/scitranslmed.aau6414","volume":"10","author":"F Borel","year":"2018","unstructured":"Borel F, Gernoux G, Sun H, Stock R, Blackwood M, Brown RH Jr et al (2018) Safe and effective superoxide dismutase 1 silencing using artificial microRNA in macaques. Sci Transl Med 10(465):eaau6414. https:\/\/doi.org\/10.1126\/scitranslmed.aau6414","journal-title":"Sci Transl Med"},{"issue":"9","key":"15_CR113","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1016\/j.ymthe.2017.05.017","volume":"25","author":"MG Biferi","year":"2017","unstructured":"Biferi MG, Cohen-Tannoudji M, Cappelletto A, Giroux B, Roda M, Astord S et al (2017) A new AAV10-U7-mediated gene therapy prolongs survival and restores function in an ALS mouse model. Mol Ther 25(9):2038\u20132052","journal-title":"Mol Ther"},{"key":"15_CR114","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.001","volume":"16","author":"R Martier","year":"2019","unstructured":"Martier R, Liefhebber JM, Garcia-Osta A, Miniarikova J, Cuadrado-Tejedor M, Espelosin M et al (2019) Targeting RNA-mediated toxicity in C9orf72 ALS and\/or FTD by RNAi-based gene therapy. Mol Ther Nucleic Acids 16:26\u201337","journal-title":"Mol Ther Nucleic Acids"},{"key":"15_CR115","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.omtn.2019.01.010","volume":"14","author":"R Martier","year":"2019","unstructured":"Martier R, Liefhebber JM, Miniarikova J, van der Zon T, Snapper J, Kolder I et al (2019) Artificial microRNAs targeting C9orf72 can reduce accumulation of intra-nuclear transcripts in ALS and FTD patients. Mol Ther Nucleic Acids 14:593\u2013608","journal-title":"Mol Ther Nucleic Acids"},{"key":"15_CR116","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/978-1-4939-3271-9_28","volume":"1382","author":"ZT McEachin","year":"2016","unstructured":"McEachin ZT, Donsante A, Boulis N (2016) Gene therapy for the treatment of neurological disorders: amyotrophic lateral sclerosis. Methods Mol Biol 1382:399\u2013408","journal-title":"Methods Mol Biol"},{"key":"15_CR117","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3389\/fnmol.2016.00056","volume":"9","author":"L Stoica","year":"2016","unstructured":"Stoica L, Sena-Esteves M (2016) Adeno associated viral vector delivered RNAi for gene therapy of SOD1 amyotrophic lateral sclerosis. Front Mol Neurosci 9:56. https:\/\/doi.org\/10.3389\/fnmol.2016.00056","journal-title":"Front Mol Neurosci"},{"issue":"18","key":"15_CR118","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.3390\/ijms20184388","volume":"20","author":"M Cappella","year":"2019","unstructured":"Cappella M, Ciotti C, Cohen-Tannoudji M, Biferi MG (2019) Gene therapy for ALS-A perspective. Int J Mol Sci 20(18):4388. https:\/\/doi.org\/10.3390\/ijms20184388","journal-title":"Int J Mol Sci"}],"container-title":["Advances in Experimental Medicine and Biology","Reviews on New Drug Targets in Age-Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-55035-6_15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T16:45:30Z","timestamp":1615913130000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-030-55035-6_15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9783030550349","9783030550356"],"references-count":118,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-55035-6_15","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"type":"print","value":"0065-2598"},{"type":"electronic","value":"2214-8019"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"17 March 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}